Welcome Guest
Home > Clinical Breast Cancer > Volume 8 | Supplement 3

Table of Contents

Volume 8 | Supplement 3

Publication Date: March 2008
  • Abstract Abstract
  • Full Text No Access
  • Full Text Pay-Per View
  • Full Text Full Text
  • Add to Cart Add to Cart


Contributions
Page Number of this Article in the Print Version
S94-S99		 Treatment of Metastatic ErbB2-Positive Breast Cancer: Options After Progression on Trastuzumab
Neil Spector
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S100-S113		 Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer
Martine Piccart
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S114-S120		 Cardiac Toxicity of ErbB2-Targeted Therapies: What Do We Know?
Edith A. Perez
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S121-S130		 Can We Circumvent Resistance To ErbB2-Targeted Agents By Targeting Novel Pathways?
Mark Pegram
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S131-S141		 Expert Roundtable: Emerging Questions in ErbB2-Positive Breast Cancer; February 22, 2007
Mark Pegram, Edith A. Perez, Martine Piccart, Neil Spector
  • Abstract
  • No Access
  • Add to Cart